Orexigen Therapeutics Schedules November 7, 2012 Conference Call and Webcast
Discussion of Financial Results for the Third Quarter Ended September 30, 2012
SAN DIEGO, Oct. 31, 2012
SAN DIEGO, Oct. 31, 2012 /PRNewswire/ -- Orexigen® Therapeutics, Inc. (Nasdaq:
OREX), a biopharmaceutical company focused on the treatment of obesity, will
announce financial results for the third quarter ended September 30, 2012 on
Wednesday, November 7, 2012 after the market closes. The announcement will be
followed by a live webcast and conference call at 5:00 p.m. Eastern time (2:00
p.m. Pacific time).
Orexigen management will host the call and webcast to discuss financial
results and recent business highlights. The live call may be accessed by phone
by calling (888) 895-5479 (domestic) or (847) 619-6250 (international),
participant code 33664518. The webcast can be accessed live on the investor
relations section of the Orexigen web site at www.orexigen.com and will be
archived for 14 days following the call.
About Orexigen Therapeutics
Orexigen Therapeutics, Inc. is a biopharmaceutical company focused on the
treatment of obesity. The Company's lead product candidate is Contrave^®,
which has completed Phase III clinical trials and for which a New Drug
Application has been submitted and reviewed by the FDA. The Company has also
reached agreement with the FDA on a Special Protocol Assessment (SPA) for the
Light Study, the Contrave cardiovascular outcomes trial. The Company's other
product candidate, Empatic™, has completed Phase II clinical trials. Further
information about the Company can be found at www.orexigen.com.
Vice President, Corporate Communications & Business Development
SOURCE Orexigen Therapeutics, Inc.
Press spacebar to pause and continue. Press esc to stop.